Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
出版日: 2021年05月13日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 115 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次


現在のパンデミックの状況や、治療やワクチン開発の必要性により、マウスモデルは幅広く様々な調査機関やバイオ医薬品産業の非臨床試験で使用されています。 ただし、多くの国が封鎖され、他国との貿易を停止したり、旅行制限を実施したりして、市場の衰退につながったため、COVID-19以外の医薬品開発におけるマウスモデルの適用は大幅に減少しています。これは市場の成長に悪影響を与える工業生産と前臨床試験の減少とともに、世界中の主要企業の時価総額の減少へと繋がっています。




第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • マウスモデルの革新の増加
    • 個別化医療に対する需要の高まり
    • 製薬およびバイオ医薬品企業のパイプラインの成長
  • 市場の抑制要因
    • 動物実験の代替案
    • 動物の倫理的使用に関する規制
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • タイプ別
    • 近交系マウス
    • 非近交系マウス
    • 遺伝子操作されたマウス
    • ハイブリッド/コンジェニックマウス
    • その他
  • サービス別
    • 育種
    • 凍結保存
    • モデルイン-ライセンス
    • 遺伝子検査
    • 他のサービス
  • テクノロジー別
    • 胚性幹細胞注射
    • 核移植
    • その他のテクノロジー
  • アプリケーション別
    • 腫瘍学
    • 心血管研究
    • 神経学
    • その他のアプリケーション
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Allentown, LLC
    • Charles River Laboratories International Inc.
    • ENVIGO
    • Genoway
    • Harbour Biomed
    • Horizon Discovery Group PLC(Sage Labs Inc.)
    • Ingenious Targeting Laboratory
    • Janvier Labs
    • Ozgene Pty Ltd.
    • PolyGene
    • Taconic Biosciences Inc.
    • The Andersons, Inc
    • The Jackson Laboratory
    • Trans Genic Inc.

第7章 市場機会と動向

Product Code: 66012

The global mice model market is expected to register a CAGR of 6.8% over the forecast period, 2021-2026.

Owing to the current pandemic situation and the urge to develop treatment and vaccine mice models have been extensively used in the pre-clinical development by various research laboratories and biopharmaceutical industries. According to an article published by the science advisory board in July 2020, researchers are using a strain of SARS-CoV-2 that can infect mice and further using it to produce a new mouse model of infection to help facilitate testing of COVID-19 vaccine candidates and therapies.

Although, there is a significant decline in the application of the mice model in drug development apart from COVID-19 because many countries had been in lockdown and have suspended the trades with other countries, implemented travel restrictions, etc., leading to declining in market capitalizations of major companies across the world, along with a decline in industrial production and pre-clinical trial which will negatively impact the market growth.

Factors such as increasing innovations in mice models, rising demand for personalized medicine, and growing pipeline of pharmaceutical and biopharmaceutical companies are driving the growth of the mice model market.

Mice models are one of the best small animal models for various infectious diseases including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Therefore these mice models are being widely used for several different viral investigations in pre-clinical researches.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), reported funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The growing demand to evaluate the effects of drugs on humans coupled with a rising focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized mice models.

In addition, Major companies are focusing on expanding their product portfolios by novel launches. In July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This novel model will save researchers months of planning and will accelerate the clinical development of NASH treatment for the treatment of liver failure.

Thus, the mice model market is expanding, with the increase in R&D activities in pharmaceutical industries. However, alternatives to animal testing and regulations for the ethical use of animals are the factors that are expected to be the restraint for the growth of the market.

Key Market Trends

Oncology Segment l is Expected to Hold the Significant Market Share Over the Forecast Period

By application by oncology, the segment is expected to hold a significant market share. The major factor propelling the growth of the segment is the rising burden of cancer coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development research. For instance, in August 2020, researchers in the meeting of the American Chemical Society reported that they are developing a new type of immunotherapy for triple-negative breast cancer. The researchers evaluated this therapy in mice models and concluded that it has dramatically extended the survival in triple-negative breast cancer in the mouse.

The Institute of Cancer Research, London stated that mice can be easily genetically altered to allow the study of the genetic causes of cancer and reproduce tumor types that naturally occur in humans for this they have been incorporating mice models in their pre-clinical trials for years. In 2017, 2018. And in 2019 ICR reported the use of 26,320, 23,525, and 25,771 mice in pre-clinical oncology testing. These mouse models are expected to revolutionize drug discovery research, such as the development and verification of various cancer therapies including cancer immunotherapy. Thus, the technological developments and funding by the major players to incorporate mice models in various stages of cancer treatment and diagnostic discoveries will boost the market growth.

North America is Expected to Dominate the Market Over the Forecast Period

Regionally, North America is expected to dominate the mice model market. The concentration of key players in the mice model market is the highest in the North American region. Additionally, the rising number of investments by the government for the development of innovations in mice models is spurring market growth.

For instance, The National Institute on Drug Abuse, United States has awarded an assistant professor at The Jackson Laboratory (JAX), an exploratory grant of USD 212,500, to identify genetic pathways involved in addiction behaviors using genome editing in mice models. Under the grant, the researchers will generate five new mice models with variation in Cyfip2 using CRISPR/Cas9 gene-editing technology.

In addition, market players are also focusing on market development strategies in order to increase their market share in the region. In April 2019, LabCorp and Envigo reported that LabCorp's Covance Drug Development segment will acquire Envigo's nonclinical research services business and Envigo's Research Models Services business will acquire the Covance Research Products business.

Also, in November 2019, Envigo announced an agreement to acquire the assets of the business unit of Horizon Discovery Group plc to combine Horizon transgenic model generation and contract breeding expertise with Envigo operational and commercial capabilities. This acquisition will boost the United State market with new products and services of mice models. All these developments are expected to increase the CAGR of the region during the forecasted period.

Competitive Landscape

The mice model market is made up of a network of players involved in research and product development, component manufacturing, distribution and sales, and post-sale services. The leading players in the market are offering services and CRISPR technologies as service models, which is experiencing an uptrend, due to increased drug development activity.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Innovation in Mice Models
    • 4.2.2 Rising Demand for Personalized Medicine
    • 4.2.3 Growing Pipeline of Pharmaceutical and Biophamraceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Alternatives to Animal Testing
    • 4.3.2 Regulations for the Ethical Use of Animals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Inbred Mice
    • 5.1.2 Outbred Mice
    • 5.1.3 Genetically Engineered Mice
    • 5.1.4 Hybrid/Congenic Mice
    • 5.1.5 Others
  • 5.2 By Service
    • 5.2.1 Breeding
    • 5.2.2 Cryopreservation
    • 5.2.3 Model in-Licensing
    • 5.2.4 Genetic Testing
    • 5.2.5 Other Services
  • 5.3 By Technology
    • 5.3.1 CRISPR/CAS9
    • 5.3.2 Embryonic Stem Cell Injection
    • 5.3.3 Nuclear Transfer
    • 5.3.4 Other Technologies
  • 5.4 By Application
    • 5.4.1 Oncology
    • 5.4.2 Cardiovascular Studies
    • 5.4.3 Neurology
    • 5.4.4 Other Applications
  • 5.5 Geography
    • 5.5.1 North America
      • United States
      • Canada
      • Mexico
    • 5.5.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.5.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.5.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allentown, LLC
    • 6.1.2 Charles River Laboratories International Inc.
    • 6.1.3 ENVIGO
    • 6.1.4 Genoway
    • 6.1.5 Harbour Biomed
    • 6.1.6 Horizon Discovery Group PLC (Sage Labs Inc.)
    • 6.1.7 Ingenious Targeting Laboratory
    • 6.1.8 Janvier Labs
    • 6.1.9 Ozgene Pty Ltd.
    • 6.1.10 PolyGene
    • 6.1.11 Taconic Biosciences Inc.
    • 6.1.12 The Andersons, Inc
    • 6.1.13 The Jackson Laboratory
    • 6.1.14 Trans Genic Inc.